This section contains information about who we are (The CAM Cancer Collaboration; our authors and reviewers and our official partners) as well as about our aims, how we are funded and about the CAM Cancer Database.
Originally funded by the European Commission (EC) within the Framework 5 Programme, CAM Cancer has been managed by the official Norwegian National Research Center for Complementary and Alternative Medicine (NAFKAM) since 2007.
NAFKAM coordinates a worldwide network of experts in CAM and/or cancer care for the CAM Cancer Collaboration, in order to produce evidence-based information on CAM for cancer thus contributing to safe and evidence-based cancer care.
NAFKAM maintains and develops the website and its content, as part of its programme of summarizing and disseminating the research status of CAM to health professionals. NAFKAM is located at the Department of Community Medicine at the Faculty of Health Sciences, UiT The Arctic University of Norway.
The aims of CAM Cancer are:
- To prepare and disseminate information for health professionals based on the best available evidence. Health professionals can use this to make informed treatment decisions together with their patients. You can access the free database of intervention types here.
- Maintaining and developing an international authoritative network around CAM in cancer. You can find out more about the CAM Cancer Collaboration here.
CAM Cancer's core output is the freely accessible database of CAM Cancer summaries published on this website. It can be accessed for free on this website by searching for treatments, symptoms or cancer types.
The CAM Cancer summaries are also available in German and are published on Onkopedia, the information portal of the German Society for Hematology and Medical Oncology (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie). Norwegian versions are available on NAFKAM‘s special section on CAM for cancer.
NAFKAM manages the CAM Cancer Collaboration supporting to fulfil the aims of CAM Cancer. The Collaboration is led by the advisory committee, the scientific coordinator and technical editor from the editorial team, and a network of official partners.
CAM-Cancer is entirely nonprofit. It receives no commercial funding or funding from any institution with a conflict of interest. The main funders of CAM-Cancer are currently NAFKAM, as well as the German Society of Hematology and Medical Oncology (DGHO) and Swiss Cancer League/ Swiss Cancer Research:
- NAFKAM is funded directly by the Norwegian government’s Directorate of Health. NAFKAM does not endorse or recommend any treatment/ therapy or any individual/ organisation providing therapy. NAFKAM’s research and information services are entirely non-profit and independent. NAFKAM’s websites do not offer advertisement of any kind.
- The German Society of Hematology and Medical Oncology (DGHO) is an organization of scientists and physicians specializing in the research, diagnosis and treatment of blood diseases and malignant solid tumors.
- The Swiss Cancer League/ Swiss Cancer Research is a national charitable organisation fighting against cancer and supporting patients and their relatives.